New York, NY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ozari Health, a New York-based telehealth company, today announced updated pricing data for its nationwide telehealth platform, where eligible patients are prescribed compounded Semaglutide starting at $86 per month and compounded Tirzepatide starting at $125 per month, all-in, with no membership fees and no long-term contracts. Alongside the update, the company released the new edition of its GLP-1 Telehealth Pricing Index, an open dataset tracking what patients actually pay across more than 90 online GLP-1 providers.
Courtesy of Ozari Health
Headline prices in the online GLP-1 market frequently exclude mandatory membership fees, dose-based surcharges, multi-month prepay requirements, and auto-renewal terms. The Pricing Index records the true all-in monthly cost for each provider, alongside whether the provider names its fulfilling pharmacy, requires a long-term commitment, or charges fees separate from the medication itself. The updated edition captures a market transformed by federal pricing agreements and new Medicare coverage, giving patients a single verified reference for what GLP-1 treatment actually costs in late 2026.
According to the updated index, all-in monthly costs for compounded semaglutide across tracked providers range widely, with many advertised prices doubling once required membership fees are included. Ozari Health's own pricing is included in the dataset on identical terms as every other provider.
"Patients comparing GLP-1 providers are comparing apples to oranges, because the advertised price and the real monthly cost are often very different numbers," said a spokesperson for Ozari Health. "We publish the index, including our own pricing, so anyone can check the math."
The dataset is published under a CC-BY-4.0 open license at ozarihealth.com/glp1-data and on Hugging Face, permitting free reuse with attribution by researchers, journalists, and patients.
Ozari Health operates a nationwide telehealth platform connecting patients with licensed, state-authorized providers who evaluate eligibility for GLP-1 treatment. Prescriptions are filled by the company's publicly named pharmacy partners: Hallandale Pharmacy, a PCAB-accredited 503A compounding pharmacy based in Fort Lauderdale, Florida, and VialsRx, a US-licensed 503A compounding pharmacy based in Texas. Both prepare patient-specific sterile medications under USP 797 standards, every medication label identifies which pharmacy filled the order, and patients choose their preferred pharmacy at standardized pricing. Before onboarding any partner, Ozari Health verifies active state licensure in good standing, USP 797 compliance, and quality documentation, with the full vetting criteria published at ozarihealth.com/pharmacy-standards. The platform maintains LegitScript certification, a third-party verification requiring ongoing review of prescribing practices, pharmacy partnerships, and marketing claims. All care is 100% online. Availability varies by state of residence.
Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. All prescriptions require review by a licensed provider who determines whether treatment is appropriate for the patient's individual medical history.
To learn more, check eligibility, or view the full Pricing Index, visit ozarihealth.com.
About Ozari Health
Ozari Health is a LegitScript-certified telehealth platform connecting patients with licensed, state-authorized providers for personalized GLP-1 treatment plans. The company partners with publicly named, US-licensed 503A compounding pharmacies to provide access to compounded Semaglutide and Tirzepatide, with transparent all-in pricing and no hidden fees. Based in New York, NY.
Press Inquiries
Mark
mark [at] ozarihealth.com
(302)316-5231
https://ozarihealth.com/
95 Worth Street
